Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
The goal of the Phase I portion of this clinical research study is to find the highest tolerated dose of the combination of thalidomide, lenalidomide, and dexamethasone that can be given to patients with relapsed or refractory MM.
The goal of the Phase II portion of this study is to learn if the drug combination can help to control the disease.
The safety of the drug combination will be studied in both phases.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|
- Maximum Tolerated Dose (MTD) [ Time Frame: End of Cycle 1 (28 Days) ] [ Designated as safety issue: Yes ]
|Study Start Date:||August 2009|
|Estimated Primary Completion Date:||August 2016 (Final data collection date for primary outcome measure)|
Experimental: Lenalidomide + Thalidomide + Dexamethasone
Lenalidomide 15 mg daily by mouth on Days 1-21 followed by 7-day rest every 28 day cycle for Cycles 1-8. Thalidomide 100 mg daily by mouth on Days 1-28 of Cycles 1-8. Dexamethasone 40 mg by mouth on Days 1-4, 9-12, and 17-20 of Cycles 1-2, and 40 mg by mouth on Days 1, 8, 15, and 21 of Cycles 3-8.
Starting dose:15 mg daily by mouth on Days 1-21 followed by 7-day rest every 28 day cycle for Cycles 1-8
Other Names:Drug: Thalidomide
Starting dose:100 mg daily by mouth on Days 1-28 of Cycles 1-8
Other Name: ThalomidDrug: Dexamethasone
40 mg by mouth on Days 1-4, 9-12, and 17-20 of Cycles 1-2.
40 mg by mouth on Days 1, 8, 15, and 21 of Cycles 3-8.
Other Name: Decadron
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00966693
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||Jatin J. Shah, MD||M.D. Anderson Cancer Center|